Physician profile
Andre M Nye
NPI 1912077538
$1,888.25
in general payments reported to CMS, 2019-2025
17 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.28 · 2021: $26.95 · 2022: $305 · 2023: $349 · 2024: $410 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.18 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $230.98 | 2022-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $186.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $176.44 | 2022 | |
| Exact Sciences Corporation | $151.25 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $134.02 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $113.73 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $100.93 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $77.28 | 2025 | |
| Merck Sharp & Dohme LLC | $68.40 | 2021-2025 | Gardasil 9, Gardasil, Vaxelis |
| Novartis Pharmaceuticals Corporation | $54.69 | 2024-2025 | |
| Edwards Lifesciences Corporation | $31.53 | 2025 | |
| Almatica Pharma LLC | $30.00 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Insulet Corporation | $23.93 | 2022 | |
| Philips North America LLC | $19.28 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.19 | 2022 | |
| Phadia US INC. | $13.08 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Nye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.